Moderna: Bullish Bancel “Not Losing Sleep” over COVID-19…
The day the Biden administration announced its support for the waiver of IP rights for COVID-19 vaccines, Moderna’s stock fell six percent; the day…
Tagged with Global
Innovative Pharma Doubles Down on IP with New Pact
On World Intellectual Property (IP) Day 2021, the innovative biopharmaceutical industry came together to launch a new initiative foregrounding the…
Pharma Logistics Under COVID: Partnerships, Digitalisation &…
The vital importance of robust supply chains and distribution networks has been foregrounded over the past year as the world struggled to ensure…
BC Platforms CEO Tero Silvola on Data’s Transformational…
CEO Tero Silvola introduces BC Platforms’ powerful data and technology platform for personalized medicine and drug development and the ‘infinity…
Novavax: From No-Hoper to COVID-19 Vaccine Saviour?
From almost being de-listed by the NASDAQ stock index in 2018 due to poor financial performance, US vaccine firm Novavax has completed a remarkable…
The COVID-19 Vaccine Rush: Nationalism, Access & IP Issues
The global rush to secure access to COVID-19 vaccines has led to accusations that richer countries are hoarding supply at the expense of poorer…
Alessandro Riva – CEO, Ichnos Sciences
Alessandro Riva, MD joined biotech Ichnos Sciences as its founding CEO in 2019, leaving behind a storied career in oncology R&D at Novartis and…
Top 5 Global CDMOs
As the global pharmaceutical industry continues to grow, so have opportunities for service providers. Over the last few decades, while big pharma…
IFPMA’s Thomas Cueni on why “#TeamVaccines is all of…
Thomas Cueni of the International Federation of Pharmaceutical Manufacturers & Associations (IFPMA) highlights the incredible progress of COVID-19…
The bright future of mRNA technology – InConversation…
Dr Thomas D. Madden, CEO and founder of Acuitas Therapeutics, shares the story behind their involvement in Pfizer and BioNTech’s COVID-19 vaccine,…
The Collaborative Spirit of Cell & Gene
One of the more intriguing aspects about the new wave of cell and gene therapies (CGT) coming onstream is that they are not just technologically…
Vaccines: Manufacturing & Supply Chain Complexity
Pharma industry insiders view vaccines as one of the most challenging products to manufacture, fundamentally due to the inherent biological…
